chartexchange

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

The Motley Fool | Nov 13, 2026 5:42 PM EST

Investors looking for stability in the healthcare sector often compare Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) . Choosing between these two industry leaders requires balancing diversified income against high-growth specialization. Amgen offers a broad range of products across oncology and rare diseases, providing a steady business model. Vertex Pharmaceuticals focuses on transformative treatments for specific genetic conditions, yielding high profitability. Both companies represent different ways to play the ongoing innovation in the medical field. Amgen discovers and manufactures medicines for a wide array of serious diseases, ranging from inflammation to oncology. It sells primarily to three large distributors, McKesson Corp. (NYSE:MCK) , Cencora Inc. (NYSE:COR) , and Cardinal Health (NYSE:CAH) , which accounted for nearly 77% of its revenues in 2025. Customer concentration like this adds a layer of risk to the business, though it also simplifies the logistics of its global distribution network. Continue reading

Read original article